Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Novo Nordisk NVO announced plans to advance amycretin, for weight management, into late-stage development. Amycretin is being ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

Despite the jump in the number of teens being prescribed Wegovy, it still represents only a small fraction of kids who are living with obesity. Approximately one in 5 children and teens in the U.S.

SEATTLE -- Weight loss drugs have gained momentum as treatment for obstructive sleep apnea (OSA) at sleep clinics across the ...

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Popular weight-loss drugs like Ozempic, Wegovy and Zepbound produce significantly less weight loss in real-world settings ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

WEDNESDAY, June 11, 2025 (HealthDay News) — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and ...

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...